Display Options:
MOLECULE TYPE: Small molecule
MECHANISMS OF ACTION: Unknown
ROUTE OF ADMINISTRATION: Unknown
STATUS: Approved
THERAPEUTIC AREA: Unknown
THERAPEUTIC INDICATION: Depressive Disorder
MOLECULE TYPE: Small molecule
MECHANISMS OF ACTION: Thiazide-sensitive sodium-chloride cotransporter inhibitor
ROUTE OF ADMINISTRATION: ORAL
STATUS: Approved
THERAPEUTIC AREA: OTHER
THERAPEUTIC INDICATION: Cardiovascular Diseases
MOLECULE TYPE: Small molecule
MECHANISMS OF ACTION: Estrogen receptor alpha agonist
ROUTE OF ADMINISTRATION: Unknown
STATUS: Approved
THERAPEUTIC AREA: Unknown
THERAPEUTIC INDICATION: Unknown
MOLECULE TYPE: Small molecule
MECHANISMS OF ACTION: 3',5'-cyclic phosphodiesterase inhibitor
ROUTE OF ADMINISTRATION: INJECTION; ORAL
STATUS: Approved
THERAPEUTIC AREA: OTHER
THERAPEUTIC INDICATION: HIV Infections; Hypertension; IgA Vasculitis; Anemia, Sickle Cell; Arthritis, Rheumatoid; Carotid Stenosis; Heart Diseases; Ovarian Neoplasms; Pancreatic Neoplasms; Takotsubo Cardiomyopathy; Angina, Stable; Myocardial Ischemia; Severe Acute Respiratory Syndrome; Coronary Artery Disease; Stroke; Thrombosis
MOLECULE TYPE: Small molecule
MECHANISMS OF ACTION: Unknown
ROUTE OF ADMINISTRATION: Unknown
STATUS: Approved
THERAPEUTIC AREA: Unknown
THERAPEUTIC INDICATION: Psychotic Disorders
MOLECULE TYPE: Small molecule
MECHANISMS OF ACTION: Unknown
ROUTE OF ADMINISTRATION: Unknown
STATUS: Approved
THERAPEUTIC AREA: Unknown
THERAPEUTIC INDICATION: Unknown
MOLECULE TYPE: Small molecule
MECHANISMS OF ACTION: Androgen Receptor agonist
ROUTE OF ADMINISTRATION: ORAL
STATUS: Approved
THERAPEUTIC AREA: OTHER
THERAPEUTIC INDICATION: Myelodysplastic Syndromes
MOLECULE TYPE: Small molecule
MECHANISMS OF ACTION: Tubulin inhibitor
ROUTE OF ADMINISTRATION: Unknown
STATUS: Approved
THERAPEUTIC AREA: Unknown
THERAPEUTIC INDICATION: Candidiasis; Infections; Tinea; Tinea Capitis; Tinea Pedis
MOLECULE TYPE: Small molecule
MECHANISMS OF ACTION: Diagnostic agent
ROUTE OF ADMINISTRATION: INJECTION; INTRAVESICAL; URETERAL
STATUS: Approved
THERAPEUTIC AREA: OTHER
THERAPEUTIC INDICATION: Unknown
MOLECULE TYPE: Small molecule
MECHANISMS OF ACTION: DNA inhibitor
ROUTE OF ADMINISTRATION: INJECTION; TOPICAL
STATUS: Approved
THERAPEUTIC AREA: OTHER
THERAPEUTIC INDICATION: Carcinoma, Renal Cell; Ependymoma; Fallopian Tube Neoplasms; Gastrointestinal Stromal Tumors; Glioma; Lymphoma; Lymphoma, Non-Hodgkin; Melanoma; Multiple Myeloma; Myelodysplastic Syndromes; Myeloproliferative Disorders; Bile Duct Neoplasms; Carcinoma, Islet Cell; Carcinoma, Merkel Cell; Carcinoma, Non-Small-Cell Lung; Digestive System Diseases; Digestive System Neoplasms; Lymphoma, AIDS-Related; Ovarian Neoplasms; Peripheral Nervous System Diseases; Peritoneal Neoplasms; Skin Neoplasms; Squamous Cell Carcinoma of Head and Neck; Thrombosis; Urethral Neoplasms; Uterine Neoplasms; Adenocarcinoma, Mucinous; Anus Neoplasms; Biliary Tract Neoplasms; Breast Neoplasms; Carcinoma; Carcinoma, Hepatocellular; Carcinoma, Neuroendocrine; Carcinoma, Pancreatic Ductal; Carcinoma, Signet Ring Cell; Carcinoma, Squamous Cell; Chalazion; Cholangiocarcinoma; Colonic Neoplasms; Colorectal Neoplasms; Colorectal Neoplasms, Hereditary Nonpolyposis; Esophageal Neoplasms; Glaucoma; Head and Neck Neoplasms; Hepatoblastoma; Hypopharyngeal Neoplasms; Inflammatory Breast Neoplasms; Kidney Neoplasms; Laryngeal Neoplasms; Liver Neoplasms; Mouth Neoplasms; Nasopharyngeal Neoplasms; Neoplasm Metastasis; Neuroendocrine Tumors; Pancreatic Neoplasms; Paranasal Sinus Neoplasms; Pharyngeal Neoplasms; Pulmonary Disease, Chronic Obstructive; Rectal Neoplasms; Squamous Intraepithelial Lesions; Stomach Neoplasms; Urinary Bladder Neoplasms; Uterine Cervical Dysplasia; Uterine Cervical Neoplasms; Vitreoretinopathy, Proliferative; Adenocarcinoma; Carcinoma, Basal Cell; Keratosis; Keratosis, Actinic; Neoplasms
MOLECULE TYPE: Small molecule
MECHANISMS OF ACTION: Sodium channel alpha subunit blocker
ROUTE OF ADMINISTRATION: ORAL
STATUS: Approved
THERAPEUTIC AREA: OTHER
THERAPEUTIC INDICATION: Amyotrophic Lateral Sclerosis; Autistic Disorder
MOLECULE TYPE: Small molecule
MECHANISMS OF ACTION: D2-like dopamine receptor antagonist
ROUTE OF ADMINISTRATION: ORAL
STATUS: Approved
THERAPEUTIC AREA: OTHER
THERAPEUTIC INDICATION: Unknown
MOLECULE TYPE: Small molecule
MECHANISMS OF ACTION: Adrenergic receptor alpha-2 agonist
ROUTE OF ADMINISTRATION: INJECTION
STATUS: Approved
THERAPEUTIC AREA: OTHER
THERAPEUTIC INDICATION: Unknown
MOLECULE TYPE: Small molecule
MECHANISMS OF ACTION: Unknown
ROUTE OF ADMINISTRATION: Unknown
STATUS: Approved
THERAPEUTIC AREA: Unknown
THERAPEUTIC INDICATION: Unknown
MOLECULE TYPE: Small molecule
MECHANISMS OF ACTION: Unknown
ROUTE OF ADMINISTRATION: Unknown
STATUS: Approved
THERAPEUTIC AREA: Unknown
THERAPEUTIC INDICATION: Unknown
MOLECULE TYPE: Small molecule
MECHANISMS OF ACTION: Unknown
ROUTE OF ADMINISTRATION: Unknown
STATUS: Approved
THERAPEUTIC AREA: Unknown
THERAPEUTIC INDICATION: Unknown
MOLECULE TYPE: Small molecule
MECHANISMS OF ACTION: Serotonin 1a (5-HT1a) receptor partial agonist
ROUTE OF ADMINISTRATION: ORAL
STATUS: Approved
THERAPEUTIC AREA: OTHER
THERAPEUTIC INDICATION: Unknown
MOLECULE TYPE: Small molecule
MECHANISMS OF ACTION: Unknown
ROUTE OF ADMINISTRATION: Unknown
STATUS: Approved
THERAPEUTIC AREA: Unknown
THERAPEUTIC INDICATION: Unknown
MOLECULE TYPE: Small molecule
MECHANISMS OF ACTION: Muscarinic acetylcholine receptor M1 antagonist
ROUTE OF ADMINISTRATION: ORAL
STATUS: Approved
THERAPEUTIC AREA: OTHER
THERAPEUTIC INDICATION: Unknown
MOLECULE TYPE: Small molecule
MECHANISMS OF ACTION: DNA inhibitor
ROUTE OF ADMINISTRATION: ORAL
STATUS: Approved
THERAPEUTIC AREA: OTHER
THERAPEUTIC INDICATION: Neoplasms
MOLECULE TYPE: Small molecule
MECHANISMS OF ACTION: Unknown
ROUTE OF ADMINISTRATION: Unknown
STATUS: Approved
THERAPEUTIC AREA: Unknown
THERAPEUTIC INDICATION: Unknown
MOLECULE TYPE: Small molecule
MECHANISMS OF ACTION: D2-like dopamine receptor antagonist
ROUTE OF ADMINISTRATION: Unknown
STATUS: Approved
THERAPEUTIC AREA: Unknown
THERAPEUTIC INDICATION: Leukemia, Myeloid, Acute; Anxiety; Dementia; Depressive Disorder; Schizophrenia; Psychotic Disorders
MOLECULE TYPE: Small molecule
MECHANISMS OF ACTION: Adrenergic receptor alpha-2 agonist
ROUTE OF ADMINISTRATION: ORAL
STATUS: Approved
THERAPEUTIC AREA: OTHER
THERAPEUTIC INDICATION: Diabetes Mellitus, Type 1; Pre-Eclampsia; Hypertension
MOLECULE TYPE: Small molecule
MECHANISMS OF ACTION: Unknown
ROUTE OF ADMINISTRATION: Unknown
STATUS: Approved
THERAPEUTIC AREA: Unknown
THERAPEUTIC INDICATION: Migraine Disorders
MOLECULE TYPE: Small molecule
MECHANISMS OF ACTION: Unknown
ROUTE OF ADMINISTRATION: ORAL
STATUS: Approved
THERAPEUTIC AREA: OTHER
THERAPEUTIC INDICATION: Unknown
MOLECULE TYPE: Small molecule
MECHANISMS OF ACTION: Progesterone receptor agonist
ROUTE OF ADMINISTRATION: ORAL; ORAL-28
STATUS: Approved
THERAPEUTIC AREA: OTHER
THERAPEUTIC INDICATION: Hepatitis C; Neoplasms; Hyperandrogenism; Multiple Sclerosis, Chronic Progressive; Multiple Sclerosis, Relapsing-Remitting; Reperfusion Injury; Dysmenorrhea; Endometriosis; Menopause; Pain; Sexual Dysfunction, Physiological
MOLECULE TYPE: Small molecule
MECHANISMS OF ACTION: Unknown
ROUTE OF ADMINISTRATION: ORAL
STATUS: Approved
THERAPEUTIC AREA: OTHER
THERAPEUTIC INDICATION: Unknown
MOLECULE TYPE: Small molecule
MECHANISMS OF ACTION: Norepinephrine transporter releasing agent
ROUTE OF ADMINISTRATION: ORAL
STATUS: Approved
THERAPEUTIC AREA: OTHER
THERAPEUTIC INDICATION: Rhinitis, Allergic, Seasonal
MOLECULE TYPE: Small molecule
MECHANISMS OF ACTION: Unknown
ROUTE OF ADMINISTRATION: Unknown
STATUS: Approved
THERAPEUTIC AREA: Unknown
THERAPEUTIC INDICATION: Castleman Disease; Lymphoma, B-Cell; Myelodysplastic Syndromes; Neoplasm Metastasis; Osteosarcoma; Precursor T-Cell Lymphoblastic Leukemia-Lymphoma; Astrocytoma; Blast Crisis; Burkitt Lymphoma; Carcinoma; Ganglioneuroblastoma; Glioblastoma; Hemangioma; Hematologic Neoplasms; Immunoblastic Lymphadenopathy; Leukemia, Lymphoid; Lymphoma, AIDS-Related; Lymphoma, Large-Cell, Anaplastic; Lymphoma, T-Cell; Optic Nerve Glioma; Purpura, Thrombocytopenic, Idiopathic; Rhabdomyosarcoma; Wilms Tumor; Brain Neoplasms; Central Nervous System Neoplasms; Choroid Plexus Neoplasms; Ependymoma; Gestational Trophoblastic Disease; HIV Infections; Hepatoblastoma; Histiocytosis, Langerhans-Cell; Hodgkin Disease; Leukemia; Leukemia, Biphenotypic, Acute; Leukemia, Lymphocytic, Chronic, B-Cell; Leukemia, Myeloid, Acute; Leukemia-Lymphoma, Adult T-Cell; Lymphoma; Lymphoma, Follicular; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Mantle-Cell; Lymphoma, Non-Hodgkin; Lymphoma, T-Cell, Peripheral; Medulloblastoma; Multiple Myeloma; Neuroblastoma; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Retinoblastoma; Rhabdomyosarcoma, Alveolar; Rhabdomyosarcoma, Embryonal; Sarcoma, Ewing; Small Cell Lung Carcinoma; Waldenstrom Macroglobulinemia; Neoplasms
MOLECULE TYPE: Small molecule
MECHANISMS OF ACTION: Thiazide-sensitive sodium-chloride cotransporter inhibitor
ROUTE OF ADMINISTRATION: ORAL
STATUS: Approved
THERAPEUTIC AREA: OTHER
THERAPEUTIC INDICATION: Cardiovascular Diseases
MOLECULE TYPE: Small molecule
MECHANISMS OF ACTION: Glucocorticoid receptor agonist
ROUTE OF ADMINISTRATION: INTRAVITREAL; OTIC; TOPICAL
STATUS: Approved
THERAPEUTIC AREA: OTHER
THERAPEUTIC INDICATION: Macular Degeneration; Retinal Diseases; Uveitis, Posterior; Otitis Externa; Dermatitis, Atopic; Dermatitis, Seborrheic; Eye Diseases; Hemorrhoids; Infections; Macular Edema; Melanosis; Psoriasis; Skin Diseases; Uveitis
MOLECULE TYPE: Small molecule
MECHANISMS OF ACTION: Unknown
ROUTE OF ADMINISTRATION: Unknown
STATUS: Approved
THERAPEUTIC AREA: Unknown
THERAPEUTIC INDICATION: Hypersensitivity; Hypotension, Orthostatic; Common Cold; Cough; Inflammation; Respiratory Tract Infections; Rhinitis; Rhinitis, Allergic, Perennial; Rhinitis, Allergic, Seasonal; Rhinitis, Vasomotor; Nasal Obstruction
MOLECULE TYPE: Small molecule
MECHANISMS OF ACTION: Histamine H1 receptor antagonist
ROUTE OF ADMINISTRATION: ORAL
STATUS: Approved
THERAPEUTIC AREA: OTHER
THERAPEUTIC INDICATION: Rhinitis, Allergic, Seasonal
MOLECULE TYPE: Small molecule
MECHANISMS OF ACTION: GABA-A receptor; anion channel positive allosteric modulator
ROUTE OF ADMINISTRATION: INJECTION; ORAL; RECTAL
STATUS: Approved
THERAPEUTIC AREA: OTHER
THERAPEUTIC INDICATION: Landau-Kleffner Syndrome; Low Back Pain; Rotator Cuff Injuries; Wounds and Injuries; Dementia; Depressive Disorder; Epilepsy, Complex Partial; Pain; Schizophrenia; Seizures; Status Epilepticus; Anxiety; Anxiety Disorders; Cerebral Palsy; Epilepsy; Mental Disorders; Psychomotor Agitation; Stiff-Person Syndrome
MOLECULE TYPE: Small molecule
MECHANISMS OF ACTION: Glutathione precursor
ROUTE OF ADMINISTRATION: INHALATION; INTRAVENOUS; ORAL
STATUS: Approved
THERAPEUTIC AREA: OTHER
THERAPEUTIC INDICATION: Aging; Altitude Sickness; Breast Neoplasms; Cardiomyopathy, Hypertrophic; Fibromyalgia; Gambling; Hearing Loss, Noise-Induced; Irritable Bowel Syndrome; Lymphoma; Mitochondrial Diseases; Neuromuscular Diseases; Niemann-Pick Disease, Type C; Polycythemia Vera; Primary Myelofibrosis; Pseudomyxoma Peritonei; Renal Insufficiency; Respiratory Tract Infections; Substance-Related Disorders; Thrombocythemia, Essential; beta-Thalassemia; Acute Lung Injury; Adrenoleukodystrophy; Alcohol Drinking; Alcoholism; Amphetamine-Related Disorders; Arrhythmias, Cardiac; Asperger Syndrome; Autistic Disorder; Bacteremia; Biliary Atresia; Bipolar Disorder; Brain Injuries; Bronchitis, Chronic; Child Development Disorders, Pervasive; Cocaine-Related Disorders; Cognitive Dysfunction; De Lange Syndrome; Dry Eye Syndromes; Epilepsy; Fuchs' Endothelial Dystrophy; Gaucher Disease; Hearing Loss; Hepatic Veno-Occlusive Disease; Homocystinuria; Ischemic Stroke; Kidney Diseases; Lupus Erythematosus, Systemic; Melanoma; Mental Disorders; Multiple Sclerosis; Multiple Sclerosis, Chronic Progressive; Muscular Diseases; Neuralgia; Neurofibromatosis 1; Obsessive-Compulsive Disorder; Pain; Parkinson Disease; Polycystic Ovary Syndrome; Premature Birth; Purpura, Thrombocytopenic, Idiopathic; Pyelonephritis; Retinitis Pigmentosa; Rhabdomyolysis; ST Elevation Myocardial Infarction; Scleroderma, Diffuse; Stress Disorders, Post-Traumatic; Stroke; Thrombocytopenia; Tobacco Use Disorder; Tourette Syndrome; Transposition of Great Vessels; Trichotillomania; Tuberculosis; Acute Kidney Injury; Anemia, Sickle Cell; Atrial Fibrillation; Bulimia Nervosa; Common Cold; Coronary Disease; Diabetic Foot; Graft vs Host Disease; Hematologic Diseases; Hepatitis, Alcoholic; Idiopathic Pulmonary Fibrosis; Infertility; Infertility, Female; Liver Failure, Acute; Marijuana Abuse; Mucositis; Myocardial Infarction; Pulmonary Disease, Chronic Obstructive; Pulmonary Fibrosis; Renal Insufficiency, Chronic; Reperfusion Injury; Respiratory Tract Diseases; Schizophrenia; Severe Acute Respiratory Syndrome; Sinusitis; Chemical and Drug Induced Liver Injury; Cystic Fibrosis; Eye Diseases; Wounds and Injuries
MOLECULE TYPE: Small molecule
MECHANISMS OF ACTION: Tubulin inhibitor
ROUTE OF ADMINISTRATION: INJECTION; INTRAVENOUS
STATUS: Approved
THERAPEUTIC AREA: OTHER
THERAPEUTIC INDICATION: Hematologic Diseases; Leukemia, Lymphoid; Melanoma; Waldenstrom Macroglobulinemia; Acquired Immunodeficiency Syndrome; Blast Crisis; Burkitt Lymphoma; Leukemia, Myeloid, Acute; Lymphohistiocytosis, Hemophagocytic; Lymphoma, AIDS-Related; Lymphoma, Large-Cell, Anaplastic; Neuroectodermal Tumors, Primitive, Peripheral; Neurofibromatosis 1; Sarcoma, Ewing; Astrocytoma; Brain Neoplasms; Carcinoma; Central Nervous System Neoplasms; Colorectal Neoplasms; Head and Neck Neoplasms; Hepatoblastoma; Hodgkin Disease; Kidney Neoplasms; Leukemia; Leukemia, Biphenotypic, Acute; Leukemia, Lymphocytic, Chronic, B-Cell; Leukemia-Lymphoma, Adult T-Cell; Lung Neoplasms; Lymphoma; Lymphoma, Follicular; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Mantle-Cell; Lymphoma, Non-Hodgkin; Lymphoma, T-Cell, Peripheral; Medulloblastoma; Mesenchymoma; Mesothelioma; Multiple Myeloma; Neoplasms; Neuroblastoma; Neuroectodermal Tumors, Primitive; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Precursor T-Cell Lymphoblastic Leukemia-Lymphoma; Retinoblastoma; Rhabdomyosarcoma; Rhabdomyosarcoma, Alveolar; Rhabdomyosarcoma, Embryonal; Sarcoma; Sarcoma, Kaposi; Uterine Cervical Neoplasms; Wilms Tumor